Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Imatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer

NCT00251225 is registered in ClinicalTrials.gov with Leonard Appleman as lead sponsor.

NCT NCT00251225
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00251225 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Imatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer
Lead sponsor
Leonard Appleman
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2005
Completion date
March 31, 2014
Enrollment
49 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer